Actemra IL-6R Binding Assays

BioOutsource has extensive experience of the design, optimization, qualification and implementation of novel binding assays suitable for the assessment of a range of monoclonal antibody therapeutics.  This provides a strong basis for the development of innovative solutions to the quantification, assessment and comparison of Actemra/RoActemra (tocilizumab) binding to both the target and to components of the immune system.

Actemra IL-6R Binding ELISA

BioOutsource has developed an Actemra IL-6R binding assay to support process development, characterization and comparability studies.  Using a traditional ELISA platform, the relative binding of the Actemra or biosimilar tocilizumab molecule to IL-6R is reported compared to a designated reference lot, along with comprehensive parallelism assessments.

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy